Tracking PRRSV Evolution: New Variants, Diagnostics, and Biosecurity in Modern Pig Production

A moving target: lineage 1 and emerging recombinants

Among the most closely watched developments in recent years has been the rise of PRRSV-2 lineage 1 variants. In the United States, a novel lineage 1C (RFLP 1-4-4) variant emerged in the Midwest beginning in late 2020 and drove substantial outbreaks across breeding and grow-finish sites. A descriptive epidemiology study documented 190 sequences from 154 pig farms in Minnesota, Iowa, and neighboring states, concentrated in a tight geographic cluster and unfolding in two transmission waves. Finishing mortality in the four weeks after detection was markedly higher in affected sites than in controls, underscoring that this was not merely a surveillance artifact but a genuinely more damaging event.

Phylodynamic analysis revealed the variant to be a recombinant, carrying a lineage 1C-like genomic backbone while having acquired a non-structural protein 2 (nsp2) segment from a lineage 1A-like virus through recombination around 2018–2019. The episode is a textbook reminder that PRRSV evolution is shaped as much by recombination as by point mutation. For diagnosticians, the practical consequence is that a single-gene test — for instance one based only on ORF5 — may misclassify a recombinant whose pieces come from different lineages, leading to wrong conclusions about outbreak sources and vaccine matching.

The lineage 1 story is not confined to North America. Across Europe and Asia, lineage 1 strains — including NADC30-like and NADC34-like progenitors — have diversified into an assortment of sublineages, some carrying the characteristic large nsp2 deletions that complicate phylogenetic assignment. Whole-genome surveillance from China has described novel recombinants that mosaic together NADC30-like, JXA1-like, and NADC34-like backbone segments, occasionally with unique amino-acid deletions in nsp2. Such complexity means that PRRSV is less a single entity than a moving family of recombinants, each with its own antigenic and virulence profile. For reference-laboratory networks, the lesson is that routine ORF5-restricted typing increasingly under-reports the true mosaicism of circulating viruses, and that whole-genome sequencing should be treated as a core surveillance activity rather than a research luxury.

Figure 1. The mature PRRSV virion consists of an internal nucleocapsid complex (nucleocapsid proteins + viral RNA). (Source: Fiers J, et al. 2024)

Air filtration and regional control programs

Because individual-herd measures alone cannot stop an airborne, regionally circulating virus, the swine industry has invested heavily in coordinated approaches. Air filtration of breeding sites — reducing the entry of aerosolized virus from neighboring farms — has become a recognized component of high-biosecurity systems. Yet filtration is only one layer. The more transformative shift has been toward voluntary regional control programs built on transparent data sharing and agreed action plans.

Research has proposed that a regional classification based on the prevalence of wild-type unstable sites: infected-high, infected-moderate, infected-low, provisional-negative, and negative. The logic is that as regional wild-type prevalence falls, participants can justify progressively more aggressive interventions, up to depopulation for elimination. Such programs depend entirely on consistent herd-status assignment — which in turn depends on reliable testing of breeding and growing sites, often using pooled oral-fluid PCR and processing-fluid sampling. Producers and veterinarians are increasingly interested in these system-level strategies, in which regional coordination, transparent data sharing, and agreed action plans replace ad-hoc herd-by-herd firefighting.

The need for standardized reagents and reference antigens

Perhaps the least glamorous but most consequential theme in modern PRRSV work is reagent standardization. Surveillance only yields comparable trend data when the antigens and antibodies used across time and space are consistent. Recombinant PRRSV N-protein antigens produced in bacterial or mammalian expression systems provide the batch-to-batch uniformity that population serosurveys require; a recombinant nucleocapsid-based indirect ELISA developed for field screening demonstrated how a locally produced antigen can support large-scale monitoring where commercial kits are costly.

On the antibody side, research-grade anti-PRRSV antibodies — including nanobody-derived detectors — improve the specificity of both ELISAs and newer formats. A nanobody-based competitive ELISA specific for genotype 2 PRRSV antibodies illustrated the potential to discriminate infections by species, an asset when vaccine and field exposures must be distinguished. Reference antigens and broadly characterized positive controls also underpin the validation of multiplex PCR and lateral-flow components, ensuring that a "negative" truly means absent rather than merely undetected because of mismatched chemistry.

Figure 2. Results of specificity verification for the one-step multiplex RT-qPCR method. (Source: Guo Z, et al. 2026)

No single tool will outpace PRRSV evolution. The realistic path forward combines disciplined regional biosecurity, transparent status classification, multiplexed molecular surveillance, and a supply of standardized, research-grade reagents that keep assays aligned with the field. For the diagnostic-reagent community, the mandate is clear: produce the antigens, antibodies, and controls that make every other layer of control measurable, comparable, and trustworthy.

The geographic texture of these searches also matters. In North America the conversation centers on airborne transmission, filtration, and coordinated regional elimination; in parts of Asia the emphasis tilts toward recombinant strain surveillance and vaccine-strain differentiation; in Europe it often converges on PRRSV-1 diversity and trade-related introduction risk. A reagent or assay portfolio that serves this global audience must therefore be validated against representatives of both species and of the major circulating lineages, not against a single convenience strain. The laboratories and suppliers that publish transparent performance data — sensitivity against low-titer field samples, specificity across genotypes, and stability of recombinant antigens — will earn the trust required to support surveillance at scale.